Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:HOWL NASDAQ:MTVA NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$15.27-7.1%$6.63$3.02▼$56.80$18.81M1.312.30 million shs189,255 shsHOWLWerewolf Therapeutics$0.44-1.8%$0.74$0.40▼$2.38$21.87M0.29652,307 shs429,651 shsMTVAMetaVia$2.38-16.2%$1.68$0.97▼$19.03$14.67M0.9110.27 million shs516,465 shsRVPHReviva Pharmaceuticals$0.60+46.6%$0.71$0.26▼$19.00$7.87M0.57565,283 shs488,430 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-18.26%-26.49%+145.52%+45.98%-74.17%HOWLWerewolf Therapeutics+3.56%+5.05%-35.55%-20.36%-62.11%MTVAMetaVia-3.87%-29.09%+89.58%+75.00%-62.90%RVPHReviva Pharmaceuticals+46.63%+45.28%-31.81%-86.07%-96.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$15.27-7.1%$6.63$3.02▼$56.80$18.81M1.312.30 million shs189,255 shsHOWLWerewolf Therapeutics$0.44-1.8%$0.74$0.40▼$2.38$21.87M0.29652,307 shs429,651 shsMTVAMetaVia$2.38-16.2%$1.68$0.97▼$19.03$14.67M0.9110.27 million shs516,465 shsRVPHReviva Pharmaceuticals$0.60+46.6%$0.71$0.26▼$19.00$7.87M0.57565,283 shs488,430 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-18.26%-26.49%+145.52%+45.98%-74.17%HOWLWerewolf Therapeutics+3.56%+5.05%-35.55%-20.36%-62.11%MTVAMetaVia-3.87%-29.09%+89.58%+75.00%-62.90%RVPHReviva Pharmaceuticals+46.63%+45.28%-31.81%-86.07%-96.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.25Hold$89.00482.84% UpsideHOWLWerewolf Therapeutics 2.14Hold$3.75748.42% UpsideMTVAMetaVia 2.00Hold$20.00740.34% UpsideRVPHReviva Pharmaceuticals 2.50Moderate Buy$66.6711,011.11% UpsideCurrent Analyst Ratings BreakdownLatest RVPH, HOWL, AKTX, and MTVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026MTVAMetaVia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/24/2026MTVAMetaVia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026RVPHReviva Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026AKTXAkari Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026AKTXAkari Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/8/2026RVPHReviva Pharmaceuticals Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2026AKTXAkari Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.003/27/2026MTVAMetaVia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $20.003/5/2026RVPHReviva Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$24.75 per shareN/AHOWLWerewolf Therapeutics$1.88M11.43N/AN/A$0.51 per share0.87MTVAMetaViaN/AN/AN/AN/A$2.31 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$1.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.30MN/AN/AN/AN/AN/A-123.29%-63.01%8/18/2026 (Estimated)HOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-208.23%-75.12%8/13/2026 (Estimated)MTVAMetaVia-$12.97M-$5.19N/AN/AN/AN/A-172.92%-89.39%8/6/2026 (Estimated)RVPHReviva Pharmaceuticals-$19.86M-$4.06N/AN/AN/AN/A-391.58%-119.08%8/13/2026 (Estimated)Latest RVPH, HOWL, AKTX, and MTVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026AKTXAkari Therapeutics-$1.33-$688.00-$686.67N/AN/AN/A5/14/2026Q1 2026MTVAMetaVia-$0.76-$0.79-$0.03-$0.79N/AN/A5/14/2026Q1 2026RVPHReviva Pharmaceuticals-$0.3550-$0.46-$0.1050-$0.46N/AN/A5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/30/2026Q4 2025AKTXAkari Therapeutics-$0.03-$2.68-$2.65-$2.6650N/AN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.270.27HOWLWerewolf TherapeuticsN/A1.271.27MTVAMetaViaN/A2.732.73RVPHReviva PharmaceuticalsN/A2.082.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%HOWLWerewolf Therapeutics64.84%MTVAMetaVia1.37%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics30.70%HOWLWerewolf Therapeutics23.60%MTVAMetaVia0.60%RVPHReviva Pharmaceuticals8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics91.14 million793,000Not OptionableHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableMTVAMetaVia85.16 million5.13 millionN/ARVPHReviva Pharmaceuticals513.11 million11.67 millionOptionableRVPH, HOWL, AKTX, and MTVA HeadlinesRecent News About These CompaniesReviva Pharmaceuticals (NASDAQ:RVPH) and Gain Therapeutics (NASDAQ:GANX) Financial ReviewJune 1 at 5:25 AM | americanbankingnews.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 26, 2026 | americanbankingnews.comReviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company ShowcaseMay 18, 2026 | finance.yahoo.comReviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company ShowcaseMay 18, 2026 | globenewswire.comOTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price SwingsMay 15, 2026 | tipranks.comReviva Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)April 21, 2026 | theglobeandmail.comMaxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress PlansApril 20, 2026 | insidermonkey.comReviva Pharmaceuticals: Reviva Announces Letter to ShareholdersApril 15, 2026 | finanznachrichten.deReviva Pharmaceuticals Holdings, Inc. Updates Shareholders on Strategic Direction and Brilaroxazine DevelopmentApril 15, 2026 | quiverquant.comQReviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00April 9, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy†from AnalystsApril 6, 2026 | defenseworld.netDRVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2April 1, 2026 | msn.comReviva Reports Full Year 2025 Financial Results and Recent Business HighlightsMarch 30, 2026 | globenewswire.comReviva Pharmaceuticals Announces One-for-Twenty Reverse Stock SplitMarch 26, 2026 | theglobeandmail.comAnalysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock SplitMarch 25, 2026 | insidermonkey.comTop 10 Stocks Under $5 That Could TripleMarch 24, 2026 | msn.comReviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingMarch 23, 2026 | finance.yahoo.comReviva Pharmaceuticals Announces $10 Million Equity OfferingMarch 19, 2026 | tipranks.comWhat's Behind The Drop In Reviva Pharmaceuticals Stock?March 19, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVPH, HOWL, AKTX, and MTVA Company DescriptionsAkari Therapeutics NASDAQ:AKTX$15.27 -1.16 (-7.06%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Werewolf Therapeutics NASDAQ:HOWL$0.44 -0.01 (-1.78%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.MetaVia NASDAQ:MTVA$2.38 -0.46 (-16.20%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more.MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Reviva Pharmaceuticals NASDAQ:RVPH$0.60 +0.19 (+46.63%) As of 06/1/2026 03:59 PM EasternReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors How the Latest Federal Contract Boosts D-Wave's Prospects 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
